The Phase III monotherapy clinical trial of Lianhuan Pharmaceutical’s LH-1801 tablets has been unblinded.
May 9, 2026
Source: drugdu
66
On the evening of May 7th, Lianhuan Pharmaceutical...(600513) issued an announcement stating that the Phase III monotherapy clinical trial of the Class 1 new drug LH-1801 tablets organized by the company has been unblinded and preliminary analysis results of the main data have been obtained recently.
The announcement indicates that LH-1801 tablets are a novel SGLT-2 inhibitor, developed by Lianhuan Pharmaceutical in collaboration with the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, and possessing independent intellectual property rights in China.A new antidiabetic drug, indicated for type 2 diabetes.
https://finance.eastmoney.com/a/202605073730257969.html
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- CanSino Biologics’ Td5cp for adolescents and adults has been included in the priority review process, accelerating its deployment of DPT protection throughout the entire life cycle. May 12, 2026
- Industry News | Harbour BioMed Announces FDA Approval of HBM7004 for the Treatment of Advanced Solid Tumors May 12, 2026
- The world’s first! GSK’s blockbuster hepatitis B drug licensed to Chia Tai Tianqing Pharmaceutical Group. May 12, 2026
- The Two Sides of RMC-6236 May 12, 2026
- A rare disease company was acquired for $4.1 billion. May 12, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
